Chemotherapy side effects collaboration underway
RUTHERFORD, N.J.—Cancer Genetics Inc. recently announced a series of multiyear collaborative studies with Moffitt Cancer Center to examine genetic variants to determine their potential as predictors of the most common side effects associated with chemotherapy treatment. The first study will work to validate and improve existing risk prediction indices of acute and delayed chemotherapy-induced nausea and vomiting. The study will ascertain if inclusion of variations of genes involved in metabolizing antiemetic drugs improves the ability to accurately predict patients that are more susceptible to chemotherapy side effects. The second collaboration will investigate how individual genetics variants affect the effectiveness of pain control for cancer patients and will seek out genetic associations for patient-reported pain outcomes. Genetic biomarkers found to be clinically significant in these studies will be integrated into Cancer Genetics' comprehensive pharmacogenomics panels.